Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

15th International Workshop on Chronic Lymphocytic Leukaemia (iwCLL 2013) /
Overview of the FCR regimen

9th - 11th Sep 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 30.09.13
Views: 4716

Prof William Wierda - MD Anderson Cancer Center, Houston, Texas, USA

Professor Wierda from MD Anderson Cancer Center, Houston, Texas, USA, gives ecancer highlights from the late-breaking presentation at iwCLL 2013 on ‘Long-term remissions after FCR chemoimmunotherapy’.  Professor Wierda outlines the history of the FCR regimen, and what the current study update that he presented at the meeting was reporting on, ie, the long-term follow-up of patients in the original FCR study.  In addition, he outlines the CLLA trial update reported by Kirsten Fischer during this iwCLL session which compared outcomes of patients treated in the front-line setting with FCR versus FC. Professor Wierda shares his highlights from these two study presentations, and suggests the patients who might do best with the FCR regimen.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation